Smartlens Secures $5.2 Million to Advance FDA Clearance and Commercial Launch of miLens

Smartlens announced the closing of an oversubscribed $5.2 million bridge financing round to accelerate the company’s FDA clearance process and support preparations for an expedited U.S. market launch of its flagship product, miLens, following a potential regulatory approval.

According to Smartlens, miLens is the world’s first electronics-free contact lens capable of continuous IOP monitoring. The technology integrates with Smartlens’ AI-powered smartphone imaging platform, enabling real-time visualization of pressure fluctuations and facilitating data-driven treatment optimization. With FDA clearance anticipated in the near term, Smartlens plans to initiate commercial activities immediately following approval. The miLens platform represents the smallest wearable microfluidic device ever developed, Smartlens stated. By providing continuous IOP data, miLens empowers physicians to personalize therapy, detect critical changes earlier, and improve long-term outcomes. According to an independent, double-blind survey of 166 ophthalmic practitioners conducted by Market Scope, 96.2% expressed intent to adopt the technology upon availability.

The financing was led by Ambit Health Ventures and also saw continued participation from existing investors including Graphene Ventures and Boutique Venture Partners, alongside new investment from Harvard Business School Alumni Angels GNY and a consortium of leading eye care providers.

“This financing milestone strengthens our position as we advance through the FDA clearance process and prepare for commercialization,” said Savas Komban, CEO and Co-Founder of Smartlens, Inc. “We’re laying the foundation for the next generation of glaucoma management—one driven by continuous, data-based insight rather than intermittent snapshots. The continued confidence from our investors underscores both the scale of the opportunity ahead and the meaningful impact miLens can have for patients worldwide.”